A vancomycin aglycon analogue that possesses a reduced C-ring and an intact E-ring chloride was prepared and its antimicrobial activity towards S. aureus and binding affinity to model cell wall ligands were established. Comparison of the derivative with a series of vancomycin aglycon analogues that possess and lack the chloro substituents on the aryl C-and E-rings defines the impact and further refines the role the C-ring chloride plays in promoting both target binding affinity and binding selectivity for D-Ala-D-Ala and its impact on antimicrobial activity.
understanding the intricacies of the binding properties of vancomycin. 13 n a recent report, we disclosed synthetic efforts capable of selective Pd(0)-catalyzed conversion of the E-ring aryl chloride in vancomycin aglycon derivatives to a boronic acid, permitting the synthesis of alternatively substituted E-ring analogues to probe the impact of this characteristic feature of the glycopeptides antibiotics. 14 Many E-ring aryl chloride substitution analogues were well tolerated and it was the presence, but not the nature, of a substituent on the E-ring that was important for maintaining binding affinity for a terminal D-Ala-D-Ala model peptide and antimicrobial activity. Herein, we disclose an initial study on the impact and role of the Cring aryl chloride through the synthesis and evaluation of the reduced C-ring vancomycin aglycon possessing the E-ring aryl chloride (3) and its comparison with a series of vancomycin aglycon analogues (2-5) that posses and lack the chloro substituents on the C and E-aryl rings ( Figure 1 , Table 1 ).
Eremomycin, a naturally occurring glycopeptide also possesses a vancomycin heptapeptide scaffold with a reduced C-ring and intact E-ring aryl chloride. 1, 15 However due to the presence of alternative amino-sugars on the periphery of the molecule, comparisons to vancomycin do not provide a clear indication as to the role of the C-ring chloride in binding and antimicrobial activity. Our studies on the selective borylation of the N-Boc vancomycin aglycon (6) revealed that a major byproduct from the reaction was the reduced C-ring aryl chloride aglycon possessing an E-ring aryl boronic acid (7, Figure 2 ). 14 For comparison, a complete series of vancomycin aglycon analogues that possess and lack the aryl chloride substituents was assembled. Compounds 4 and 5 which lacked the E-ring chloride and both C-and E-ring aryl chlorides, respectively, were prepared as previously described by Harris through hydrogenation of vancomycin aglycon. 16 The antimicrobial activity of vancomycin and the vancomycin aglycon analogues 2-5 against sensitive S. aureus were obtained according to a standard microtiter plate-based antimicrobial assay (Table 2) Table 2 . 18 These ligands represent known (X = Gly) and additional possible vancomycin binding sites in the bacterial cell wall of resistant bacteria (X = D-Ser).
Removal of just the C-ring aryl chloride with 3 led to a >8-fold drop in activity against sensitive S. aureus compared to the vancomycin aglycon. This loss in activity was more substantial than the decrease in activity seen upon the selective removal of the E-ring aryl chloride in 4. The difference in antimicrobial activity can be explained through ligand binding studies with N,N′-Ac 2 -L-Lys-D-Ala-D-Ala, which revealed that selective removal of the C-ring chloride with 3 led to an approximate 4-fold loss in binding, whereas the selective E-ring chloride removal with 4 led to a smaller 2-fold decrease in binding affinity. Interestingly, the loss of binding for 3 and 4 for D-Ala-D-Ala are additive and explain the poorer binding observed for the analogue 5, lacking both the C-and E-ring chlorides. These observations further refine the role of the C-ring aryl chloride in target binding selectivity and binding affinity. Its presence helps define the vancomycin binding pocket and increase binding affinity for terminal D-Ala-D-Ala ligands over alternative bacterial cell wall binding sites and its impact is larger than that of the E-ring chloride. Additionally, the comparative binding studies of 2 and 3 with model cell wall ligands provide a valuable insight into and starting point for evaluating C-ring analogues replacing the chloride with alternative substituents.
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Refer to Web version on PubMed Central for supplementary material. Vancomycin and vancomycin aglycon analogues. (a) (HO) 4 B 2 (3 eq), X-Phos-Pd-G2 (0.3 eq), KOAc (3 eq), X-Phos (0.6 eq), EtOH, 60 °C, 6 h, 19% 7. (b) CuCl 2 , MeOH/H 2 O (60 °C, 2 h) then TFA/CH2Cl2, (25 °C, 20 min), 52% (two steps) R 1 = R 2 = H, R 3 = Cl, R 4 = H. Table 2 Binding and Antimicrobial Properties. 
